169 related articles for article (PubMed ID: 37929279)
41. Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy.
Topletz AR; Le HN; Lee N; Chapman JD; Kelly EJ; Wang J; Isoherranen N
Drug Metab Dispos; 2013 Feb; 41(2):312-9. PubMed ID: 23150428
[TBL] [Abstract][Full Text] [Related]
42. The Atypical Antipsychotic Lurasidone Affects Brain but Not Liver Cytochrome P450 2D (CYP2D) Activity. A Comparison with Other Novel Neuroleptics and Significance for Drug Treatment of Schizophrenia.
Danek PJ; Daniel WA
Cells; 2022 Nov; 11(21):. PubMed ID: 36359909
[TBL] [Abstract][Full Text] [Related]
43. Whole genome detection of sequence and structural polymorphism in six diverse horses.
Al Abri MA; Holl HM; Kalla SE; Sutter NB; Brooks SA
PLoS One; 2020; 15(4):e0230899. PubMed ID: 32271776
[TBL] [Abstract][Full Text] [Related]
44. CYP2D in the brain.
Funae Y; Kishimoto W; Cho T; Niwa T; Hiroi T
Drug Metab Pharmacokinet; 2003; 18(6):337-49. PubMed ID: 15618754
[TBL] [Abstract][Full Text] [Related]
45. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.
Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacoz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1995 Oct; 40(4):361-7. PubMed ID: 8554938
[TBL] [Abstract][Full Text] [Related]
46. Identification of genetic variation in equine collagenous lectins using targeted resequencing.
Fraser RS; Arroyo LG; Meyer A; Lillie BN
Vet Immunol Immunopathol; 2018 Aug; 202():153-163. PubMed ID: 30078590
[TBL] [Abstract][Full Text] [Related]
47. Applied equine genetics.
Finno CJ; Bannasch DL
Equine Vet J; 2014 Sep; 46(5):538-44. PubMed ID: 24802051
[TBL] [Abstract][Full Text] [Related]
48. Equine influenza vaccination as reported by horse owners and factors influencing their decision to vaccinate or not.
Bambra W; Daly JM; Kendall NR; Gardner DS; Brennan M; Kydd JH
Prev Vet Med; 2020 Jul; 180():105011. PubMed ID: 32438206
[TBL] [Abstract][Full Text] [Related]
49. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes.
Masubuchi Y; Iwasa T; Hosokawa S; Suzuki T; Horie T; Imaoka S; Funae Y; Narimatsu S
J Pharmacol Exp Ther; 1997 Sep; 282(3):1435-41. PubMed ID: 9316857
[TBL] [Abstract][Full Text] [Related]
50. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.
Wright GE; Niehaus DJ; Drögemöller BI; Koen L; Gaedigk A; Warnich L
Ann Hum Genet; 2010 Jul; 74(4):340-50. PubMed ID: 20597905
[TBL] [Abstract][Full Text] [Related]
51. Pharmacogenetics: the molecular genetics of CYP2D6 dependent drug metabolism.
Wong JY; Seah ES; Lee EJ
Ann Acad Med Singap; 2000 May; 29(3):401-6. PubMed ID: 10976397
[TBL] [Abstract][Full Text] [Related]
52. Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population.
Ahmed S; Zhou J; Zhou Z; Chen SQ
Genes (Basel); 2018 Oct; 9(10):. PubMed ID: 30360443
[TBL] [Abstract][Full Text] [Related]
53. Identification and genetic characterization of a novel parvovirus associated with serum hepatitis in horses in China.
Lu G; Sun L; Ou J; Xu H; Wu L; Li S
Emerg Microbes Infect; 2018 Oct; 7(1):170. PubMed ID: 30348940
[TBL] [Abstract][Full Text] [Related]
54. Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice.
Stocco MR; Tolledo C; Wadji FB; Gonzalez FJ; Miksys S; Tyndale RF
Mol Neurobiol; 2020 Nov; 57(11):4608-4621. PubMed ID: 32761352
[TBL] [Abstract][Full Text] [Related]
55. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
56. Identification of the novel polymorphisms and potential genetic features of the prion protein gene (PRNP) in horses, a prion disease-resistant animal.
Kim YC; Won SY; Do K; Jeong BH
Sci Rep; 2020 Jun; 10(1):8926. PubMed ID: 32488112
[TBL] [Abstract][Full Text] [Related]
57. Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: an evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism.
Uno Y; Uehara S; Kohara S; Murayama N; Yamazaki H
Drug Metab Dispos; 2014 Sep; 42(9):1407-10. PubMed ID: 24985704
[TBL] [Abstract][Full Text] [Related]
58. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
[TBL] [Abstract][Full Text] [Related]
59. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
60. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M
Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
